Chronic Lymphocytic Leukemia
We recommend
OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?
Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…
Articles on this topic
Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an…
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these...
Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells…
Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL – 5-Year Follow-Up Data
At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated…
Seventy-day Shedding of SARS-CoV-2 in an Immunocompromised Patient with CLL – A Case Study
A team of American and British experts published the case of a 71-year-old woman with chronic…
Older patients with CLL and comorbidities: an option for treatment with immunotherapy without chemotherapy?
Is it time to treat chronic lymphocytic leukemia (CLL) without chemotherapy? The authors of a…
Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL
Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL),…
What Next for Patients with CLL After Stopping Venetoclax?
Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based…
Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal…
Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Chronic lymphocytic leukaemia – contemporary application of modern prognostic and predictive markers in diagnostics
- Venetoclax Treatment Strategies in Patients with CLL
- Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
- Evolution of chronic lymphocytic leukemia treatment over the past 25 years
- Current Treatment Options for Refractory/Relapsed CLL
- Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
Journal on this topic
Related topic